Cellular antitumor immune response to a branched lysine multiple antigenic peptide containing epitopes of a common tumor-specific antigen in a rat glioma model

Cancer Immunology, Immunotherapy

Volumn 54, Issue 2, 2005, Pages 107-119

  Ciesielski, Michael J ^a   Kazim, A Latif ^a   Barth, Rolf F ^b   Fenstermaker, Robert A ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Epidermal growth factor receptor; Glioma; Immunity; Peptide; Tumor antigen; Vaccine

Indexed keywords

CANCER VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPITOPE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 4; LYSINE; MULTIPLE ANTIGENIC PEPTIDE VACCINE; PEPTIDE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; CANCER IMMUNOLOGY; CELLULAR IMMUNITY; CONTROLLED STUDY; GLIOMA; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; LYSIS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SPLEEN CELL; SURVIVAL; T LYMPHOCYTE; TH1 CELL; TH2 CELL; VACCINATION; WILD TYPE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; BRAIN NEOPLASMS; CANCER VACCINES; EPITOPES; GLIOMA; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; INTERLEUKIN-4; LYSINE; MALE; MODELS, ANIMAL; PEPTIDE FRAGMENTS; RATS; RATS, INBRED F344; RECEPTOR, EPIDERMAL GROWTH FACTOR; SPLEEN; SURVIVAL RATE; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; TH2 CELLS; VACCINATION;

EID: 11944266853     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-004-0576-y     Document Type: Article

References (47)

1. Wingo PA, Tong T, Bolden S (1995) Cancer statistics. CA Cancer J Clin 45:8-30
2. Desmeules M, Mikkelsen T, Mao Y (1992) Increasing incidence of primary malignant brain tumors: influence of diagnostic methods. J Natl Cancer Inst 84:442-445
3. McKinley B, Michalek A, Plunkett RJ, Fenstermaker RA (2000) The impact of age and sex on the incidence of glial tumors in New York State from 1976 to 1995. J Neurosurg 93:932-939
4. Halperin EC, Burger PC, Bullard DE (1988) The fallacy of the localized supratentorial malignant glioma. Int J Radiat Oncol Biol Phys 15:505-509
5. Libermann TA, Nusbaum HR, Razon N et al (1985) Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 313:144-147
6. Humphrey PA, Wong AJ, Vogelstein B et al (1988) Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts. Cancer Res 48:2231-2238
7. Bigner SH, Humphrey PA, Wong AJ et al (1990) Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer Res 50:8017-8022
8. Wong AJ, Bigner SH, Bigner DD et al (1987) Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci U S A 84:6899-6903
9. Ekstrand AJ, James CD, Cavenee WK et al (1991) Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res 51:2164-2172
10. Sugawa N, Ekstrand AJ, James CD, Collins VP (1990) Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci U S A 87:8602-8606
11. Humphrey PA, Gangarosa LM, Wong AJ et al (1991) Deletion-mutant epidermal growth factor receptor in human gliomas: effects of type II mutation on receptor function. Biochem Biophys Res Commun 178:1413-1420
12. Wong AJ, Ruppert JM, Bigner SH et al (1992) Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci U S A 89:2965-2969
13. Fenstermaker RA, Ciesielski MJ (2000) Deletion and tandem duplication of exons 2-7 in the epidermal growth factor receptor gene of a human malignant glioma. Oncogene 19:4542-4548
14. Frederick L, Eley G, Wang XY, James CD (2000) Analysis of genomic rearrangements associated with EGFRvIII expression suggests involvement of Alu repeat elements. Neurooncology 2:159-163
15. Garcia de Palazzo IE, Adams GP, Sundareshan P et al (1993) Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas. Cancer Res 53:3217-3220
16. Moscatello DK, Holgado-Madruga M, Godwin AK et al (1995) Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 55:5536-5539
17. Wikstrand CJ, Hale LP, Batra SK et al (1995) Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res 55:3140-3148
18. Moscatello DK, Ramirez G, Wong AJ (1997) A naturally occurring mutant epidermal growth factor receptor as a target for peptide vaccine immunotherapy of tumors. Cancer Res 57:1419-1424
19. Heimberger AB, Crotty LE, Archer GE, Hess KR, Wikstrand CJ, Friedman AH, Friedman HS, Bigner DD, Sampson JH (2003) Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res 9(11):4247-4254
20. Tam JP (1988) Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system. Proc Natl Acad Sci U S A 85:5409-5413
21. Bhasin M, Singh H, Raghava GPS (2003) MHCBN: a comprehensive database of MHC binding and non-binding peptides. Bioinformatics 19:666-667
22. Rammensee H-G, Bachmann J, Emmerich NN, Bachor OA, Stevanovic S (1999) SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50:213-219
23. Ciesielski MJ, Fenstermaker RA (2000) Oncogenic epidermal growth factor receptor mutants with tandem duplication: gene structure and effects on receptor function. Oncogene 19:810-820
24. Gogal RM, Ahmed SA, Holladay SD et al (2000) Induced minor malformations in the neocortex of normal mice do not alter immunological functions. Immunol Invest 29:299-318
25. Ahmed SA, Gogal RM, Walsh JE (1994) A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: an alternative to [3H]thymidine incorporation assay. J Immunol Methods 170:211-224
26. Kwack K, Lynch RG (2000) A new non-radioactive method for IL-2 bioassay. Mol Cells 10:575-578
27. Wu G, Barth RF, Yang W, Chatterjee M, Tjarks W, Ciesielski MJ, Fenstermaker RA (2004) Site-specific conjugation of boron-containing dendrimers to anti-EGF receptor monoclonal antibody cetuximab (IMC-C225) and its evaluation as a potential delivery agent for neutron capture therapy. Bioconjug Chem 15(1):185-194
28. Mustafa MI, Diener P, Hojeberg B et al (1991) T cell immunity and interferon-gamma secretion during experimental allergic encephalomyelitis in Lewis rats. J Neuroimmunol 31:165-177
29. Elghazali G, Perlmann H, Rutta AS et al (1997) Elevated plasma levels of IgE in Plasmodium falciparum-primed individuals reflect an increased ratio of IL-4 to interferon-gamma (IFN-gamma)-producing cells. Clin Exp Immunol 109:84-89
30. van der Meide PH, de Labie MC, Botman CA et al (1993) Mercuric chloride down-regulates T cell interferon-gamma production in Norway but not in Lewis rats; role of glutathione. Eur J Immunol 23:675-681
31. Barth RF (1998) Rat brain tumor models in experimental neuro-oncology: the 9L, C6, T9, RG2 (D74), RT-2 and CNS-1 gliomas. J Neuro-oncol 36:91-102
32. Barth RF, Yang W, Adams DM et al (2002) Molecular targeting of the epidermal growth factor receptor for neutron capture therapy of gliomas. Cancer Res 62:3159-3166
33. Tzeng J-J, Barth RF, Orosz CG, James S (1991) Phenotype and functional activity of tumor-infiltrating lymphocytes isolated from immunogenic and nonimmunogenic rat brain tumors. Cancer Res 51:2373-2378
34. Tzeng J-J, Barth RF, Orosz CG (1992) Quantitation of glioma-reactive cytolytic T lymphocyte precursors by means of limiting dilution analysis. J Immunol Methods 146:177-184
35. Tzeng JJ, Barth RF, Clendenon NR, Gordon WA (1990) Adoptive immunotherapy of a rat glioma using lymphokine-activated killer cells and interleukin-2. Cancer Res 50:4338-4343
36. Gainer AL, Young ATL, Parney IF et al (2000) Gene gun transfection of human glioma and melanoma cell lines with genes encoding human IL-12 and GM-CSF. J Neuro-oncol 47:23-30
37. Herrlinger U, Kramm CM, Johnston KM et al (1997) Vaccination for experimental gliomas using GM-CSF-transduced glioma cells. Cancer Gene Ther 4:345-352
38. Sedegah M, Weiss W, Sacci JB et al (2000) Improving protective immunity induced by DNA-based immunization: priming with antigen and GM-CSF-encoding plasmid DNA and boosting with antigen-expressing recombinant poxvirus. J Immunol 164:5905-5912
39. Disis ML, Bernhard H, Shiota FM et al (1996) Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines. Blood 88:202-210
40. Ohman L, Gedda L, Hesselager G et al (2002) A new antibody recognizing the vIII mutation of human epidermal growth factor receptor. Tumor Biol 23:61-69
41. Wikstrand CJ, Cole VR, Crotty LE et al (2002) Generation of anti-idiotypic reagents in the EGFRvIII tumor-associated antigen system. Cancer Immunol Immunother 50:639-652
42. Luwor RB, Johns TG, Murone C et al (2001) Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the del2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR. Cancer Res 61:5355-5361
43. Petch LA, Harris J, Raymond VW et al (1990) A truncated, secreted form of the epidermal growth factor receptor is encoded by an alternatively spliced transcript in normal rat tissue. Mol Cell Biol 10:2973-2982
44. Ullrich A, Coussens L, Hayflick JS et al (1984) Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 309:418-425
45. Brooks WH, Netsky MG, Normansell DE, Horwitz DA (1972) Depressed cell-mediated immunity in patients with primary intracranial tumors: characterization of a humoral immunosuppressive factor. J Exp Med 136:1631-1647
46. Mahaley MS, Brooks WH, Roszman TL et al (1977) Immunobiology of primary intracranial tumors, Part 1: studies of the cellular and humoral general immune competence of brain-tumor patients. J Neurosurg 46:467-476
47. Wagner JR, Walther MM, Linehan WM et al (1999) Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place. J Urol 162:43-45